Enveric Biosciences Inc. ENVB on Tuesday highlighted preclinical findings for its lead candidate EB-003. It pointed to rapid ...
EB-003 revealed to also act as an agonist of the serotonin receptor 5-HT1B, a validated target of drugs approved to treat major depressive disorder and a variety of neurological conditions including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results